fbpx

OptiLight IPL Dry Eye Treatment With Mandy Moore

New FDA-Approved Dry Eye Treatment for Meibomian Gland Dysfunction is available at the Dry Eye Center of Maryland

Mandy Moore Partners With Lumenis to Raise Awareness of Dry Eye Disease and OptiLight Treatment

  • Ms. Moore has partnered with Lumenis as a brand ambassador for OptiLight to tell her story and empower others.
  • After suffering for years with dry, itchy, burning eyes, Ms. Moore learned her problem was dry eye disease—a condition that affects millions of people. After undergoing treatment with OptiLight, Ms. Moore’s quality of life greatly improved.
  • OptiLight is a revolutionary, patented treatment that is the first and only light-based therapy for dry eye disease.

Yokne’am Illit, Israel – Lumenis today announced that it has partnered with singer-songwriter and actress Mandy Moore as a brand ambassador for OptiLight, a bright solution for dry eyes. Ms. Moore suffered from dry eye disease and treatment with OptiLight significantly improved her condition. Now she’s partnering with Lumenis to share her story and empower others. She will star in OptiLight’s new campaign, showing millions of dry eye sufferers that they don’t have to “just live with it”.
Before she was diagnosed, Ms. Moore didn’t realize that her dry, itchy, burning eyes were actually signs of a condition called dry eye disease. Dry eye disease is remarkably common, affecting an estimated 49 million Americans, yet only half are diagnosed.1,2 To help dry eye sufferers like Ms. Moore, Lumenis, the world’s largest energy-based medical device company for eye care and aesthetics applications, recently launched OptiLight. This revolutionary, patented treatment is the first and only light-based therapy for dry eye disease. As part of a treatment regimen, OptiLight helps improve dry eye disease with a series of quick, gentle, in-office treatments.

The Dry Eye Center of Maryland is now offering the first and only IPL FDA approved for Dry Eye Management. The Dry Eye Center of Maryland is excited to introduce OptiLight - FDA IPL for Dry Eye Syndrome. Lumenis, the inventor of IPL, presents the first and only IPL FDA-approved for the management of dry eye disease due to MGD.

“I’m excited to partner with Lumenis and share how OptiLight has made a real impact on my life. For years, I suffered from dry eye disease, but I didn’t know I had it! My eyes felt gritty and tired, and they looked red. I couldn’t wear my contact lenses for long. Eye drops didn’t do much. It was a constant frustration on the set and at home with my family,” said Ms. Moore. “When I learned that I had a medical condition called dry eye disease, I realized I didn’t have to just live with it—I could get a safe, effective treatment with OptiLight. Now, I can focus more time on what’s important to me, rather than battling the constant nuisance and discomfort of dry eye disease, and I want to inspire other people to say, ‘I won’t just live with it.’”
The “Not Gonna Live With It Generation” campaign featuring Ms. Moore debuted today with a commercial as well as a digital and print media campaign to encourage people to learn more about dry eye disease and find effective therapy with OptiLight.
“Lumenis is thrilled to partner with Mandy Moore for this important campaign, which will raise awareness of dry eye disease and introduce groundbreaking treatment with OptiLight,” said Lumenis CEO Tzipi Ozer-Armon. “OptiLight with patented Optimal Pulse Technology (OPT) is the only light therapy for the management of dry eye disease. For millions of people who share Mandy’s experience with this condition, OptiLight is a perfect fit. Our ability to improve the quality of life for those who suffer from dry eye disease is why we do what we do, so it’s wonderful to see her enthusiasm for OptiLight and the results of her treatment. We hope it will inspire others to get better care for dry eye disease.”

To learn more about dry eye disease and OptiLight, visit TreatMyDryEye.com and follow Lumenis on InstagramFacebook and LinkedIn with #NotGonnaLiveWithIt and #OptiLight.